Edition:
United Kingdom

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

171.28USD
24 May 2019
Change (% chg)

$-0.83 (-0.48%)
Prev Close
$172.11
Open
$172.62
Day's High
$173.74
Day's Low
$171.09
Volume
963,444
Avg. Vol
1,190,829
52-wk High
$210.18
52-wk Low
$166.30

Select another date:

Wed, May 22 2019

Photo

Amgen to buy Copenhagen-based Nuevolution for $167 million

Amgen, the world's largest biotechnology company, agreed on Wednesday to buy Scandinavian biopharmaceutical company Nuevolution AB for 1.61 billion Swedish crowns ($166.8 million) to boost its position in drug discovery.

UPDATE 1-Amgen to buy Copenhagen-based Nuevolution for $167 mln

May 22 Amgen, the world's largest biotechnology company, agreed on Wednesday to buy Scandinavian biopharmaceutical company Nuevolution AB for 1.61 billion Swedish crowns ($166.8 million) to boost its position in drug discovery.

Amgen offers to buy Copenhagen-based Nuevolution for $167 mln

May 22 Amgen, the world's largest biotechnology company, said on Wednesday it offered to buy Scandinavian biopharmaceutical company Nuevolution AB for 1.61 billion Swedish crowns ($166.8 million).

Lilly's new migraine drug pulls ahead of Amgen in fierce battle for new prescriptions

INDIANAPOLIS Eli Lilly and Co has pulled ahead in a three-way race with Amgen Inc and Teva Pharmaceutical Industries Ltd in attracting new patients to a new class of migraine drugs, and seeks to build on that advantage by stressing that its therapy can completely prevent headaches in a small percentage of patients.

UPDATE 1-Lilly's new migraine drug pulls ahead of Amgen in fierce battle for new prescriptions

INDIANAPOLIS, May 10 Eli Lilly and Co has pulled ahead in a three-way race with Amgen Inc and Teva Pharmaceutical Industries Ltd in attracting new patients to a new class of migraine drugs, and seeks to build on that advantage by stressing that its therapy can completely prevent headaches in a small percentage of patients. Weekly U.S. prescription data from IQVIA, an analytics provider to the life sciences industry, showed that Lilly’s therapy Emgality claimed the largest share of fi

Lilly's new migraine drug pulls ahead of Amgen in fierce battle for new prescriptions

INDIANAPOLIS, May 10 Eli Lilly and Co has pulled ahead in a three-way race with Amgen Inc and Teva Pharmaceutical Industries Ltd in attracting new patients to a new class of migraine drugs, and seeks to build on that advantage by stressing that its therapy can completely prevent headaches in a small percentage of patients. Weekly U.S. prescription data from IQVIA, an analytics provider to the life sciences industry, showed that Lilly’s therapy Emgality claimed the largest share of fi

Amgen revenue flat as migraine, cholesterol drugs miss sales expectations

Amgen Inc on Tuesday reported first-quarter revenue that was unchanged from a year ago as key drugs, including new migraine treatment Aimovig and cholesterol fighter Repatha, face pricing pressure.

UPDATE 2-Amgen revenue flat as migraine, cholesterol drugs miss sales expectations

April 30 Amgen Inc on Tuesday reported first-quarter revenue that was unchanged from a year ago as key drugs, including new migraine treatment Aimovig and cholesterol fighter Repatha, face pricing pressure.

Amgen revenue flat for first quarter, Aimovig, Repatha fall short of sales expectations

April 30 Amgen Inc on Tuesday reported first-quarter revenue that was unchanged from a year ago and net income fell 14 percent as sales of key drugs, including new migraine treatment Aimovig and cholesterol fighter Repatha, face competition and pressure to lower prices.

Drugmakers Astellas, Amgen to pay $125 million in U.S. charity kickback probe

BOSTON Two drugmakers will pay nearly $125 million (97 million pounds) to resolve claims they used charities that help cover Medicare patients' out-of-pocket drug costs as a way to pay kickbacks aimed at encouraging the use of their high-priced medications, the U.S. Justice Department said on Thursday.

Select another date: